Mercy Health - Willard Hospital | |
1100 Neal Zick Road, Willard, Ohio 44890 | |
(419) 964-5000 | |
Name | Mercy Health - Willard Hospital |
---|---|
Type | Critical Access Hospital |
Location | 1100 Neal Zick Road, Willard, Ohio |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 361310 |
NPI Number | 1528152634 |
Organization Name | MERCY HEALTH - WILLARD HOSPITAL LLC |
Doing Business As | HARNESS HEALTH PHARMACY |
Address | 1100 Neal Zick Rd, Willard, OH 44890 |
Hospital Type | General Acute Care Hospital |
Phone Number | 419-964-5000 |
News Archive
AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.
Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.
Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.
A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.
› Verified 1 days ago
NPI Number | 1790731016 |
Organization Name | MERCY HEALTH - WILLARD HOSPITAL LLC |
Doing Business As | SISTERS OF MERCY OF WILLARD, OHIO |
Address | 1100 Neal Zick Road, Willard, OH 44890 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 419-964-5000 |
News Archive
AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.
Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.
Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.
A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.
› Verified 1 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
AvidBiotics today announced the receipt of two new grants totaling $1 million dollars from the National Institutes of Health that further the development of the company's novel Avidocin™ platform for narrow spectrum antibacterial proteins against important health care threats. These grants add to three previous grants covering AvidBiotics' anti-infectious disease technologies, which provide approximately $3.4 million in currently active funding for the company.
Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,855,167. The invention describes technologies and high-throughput methods for identifying bimolecular interactions in vivo based on protein-fragment complementation assays.
Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor, a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.
A new study has shown that SGLT-2 inhibitors used in the treatment of type 2 diabetes do not increase the risk of UTIs over other anti-diabetic medications.
› Verified 1 days ago
Mercy Health - Willard Hospital Critical Access Hospital Location: 1100 Neal Zick Road, Willard, Ohio 44890 Phone: (419) 964-5000 |